Minus the $17m cash raise makes the offer about the same as DYLs last much maligned offer.To me we sold out too cheap but the VMY board didn't have the balls to go it alone basically, that's the way I see it.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%